Which natural DHT blockers have real evidence?

Saw palmetto is the best-supported botanical. Pumpkin seed oil and beta-sitosterol, green tea EGCG, zinc and pygeum each have a narrower evidence base, and the article states where each one stops.

Does oral or topical make a difference?

Yes, and it is the distinction nobody explains. An ingredient studied orally does not automatically transfer to a topical formulation, or the reverse.

The honourable mentions and the ingredients with no meaningful support are named directly, rather than left in as filler.

Natural DHT Blockers: What the Science Supports, What It Doesn't

2026年8月17日

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc. — Drug-Free Hair Regrowth Series

Somewhere in the last few months you learned the word DHT, and it reorganized how you think about your hair. The widening part, the thinning temples, the ponytail that keeps getting smaller — suddenly there was a mechanism, and a villain.

Then you searched for what to do about it, and you found two worlds that barely speak to each other. One is pharmaceutical: finasteride, dutasteride, effective and well studied and — if you are a woman who could become pregnant — categorically off the table. The other is a wall of supplements promising to "block DHT naturally," most of them citing the same handful of studies most of them have not read.

I want to walk you through what the botanical evidence actually supports, honestly, with effect sizes rather than adjectives. Some of these ingredients have real published data. Some have almost none and are sold as though they do. And there is one distinction — topical versus oral — that changes the entire risk calculation, particularly for women, and almost nobody explains it.

Let me be clear about my own position: I formulate drug-free products, which means I have a stake in this conversation. That is exactly why I'm going to give you the limitations first and the enthusiasm second.

First, the Enzyme: What You're Actually Trying to Block

DHT — dihydrotestosterone — is not an invader. It is a normal androgen produced from testosterone by an enzyme called 5-alpha-reductase (5αR). In genetically susceptible follicles, DHT binds androgen receptors and initiates progressive miniaturization: each growth cycle produces a shorter, finer, less pigmented hair, until the follicle produces nothing visible at all.

The enzyme comes in two isoforms that matter here:

Type I 5αR is expressed in sebaceous glands, skin, and scalp — including the sebaceous glands directly associated with hair follicles.

Type II 5αR is concentrated in the prostate, genital skin, and — critically — the dermal papilla of scalp hair follicles, the follicle's control center. Type II is the dominant player in androgenetic alopecia.

This is why isoform selectivity matters when you compare interventions. Finasteride inhibits primarily Type II. Dutasteride inhibits both. Sawaya and Price demonstrated in the Journal of Investigative Dermatology that scalp follicles from balding individuals show measurably different levels of 5αR Type I and Type II, aromatase, and androgen receptor compared with non-balding scalp — the enzymatic environment, not just circulating hormone levels, distinguishes affected from unaffected follicles (Sawaya & Price, 1997).

The practical consequence: this is a local, tissue-level problem. Which is the entire basis for the topical argument I'll make below.

The Ingredient-by-Ingredient Evidence

Saw palmetto (Serenoa repens) — the best-supported botanical

Saw palmetto is the most-studied of the botanical 5αR inhibitors, and its evidence base is genuinely respectable while still being modest.

Prager and colleagues (2002), in the Journal of Alternative and Complementary Medicine, ran a randomized, double-blind, placebo-controlled trial of a botanically derived 5αR inhibitor formulation containing saw palmetto in men with mild-to-moderate androgenetic alopecia. Sixty percent of treated subjects were rated improved versus 11% on placebo. That is a real placebo-controlled result — but note the sample was small (n=26 completing) and the outcome was investigator rating rather than hair count.

Rossi and colleagues (2012), in the International Journal of Immunopathology and Pharmacology, compared oral saw palmetto against finasteride over two years in men with androgenetic alopecia. Roughly 38% of the saw palmetto group showed improvement, versus about 68% on finasteride. Saw palmetto was more effective in the frontal region than the vertex.

I want you to sit with that comparison rather than skip past it, because it is the honest headline of this entire article: saw palmetto worked, and it worked roughly half as well as the drug. Anyone selling you saw palmetto as equivalent to finasteride is misrepresenting the best data we have. Anyone dismissing it as inert is also wrong.

Mechanistically, saw palmetto's lipophilic extract inhibits both 5αR isoforms in vitro and appears to interfere with DHT binding to androgen receptors. Wessagowit and colleagues reported improvement with topical products containing Serenoa repens extract in men with androgenetic alopecia (Wessagowit et al., 2016).

Pumpkin seed oil and beta-sitosterol

Cho and colleagues (2014) published a 24-week randomized, double-blind, placebo-controlled trial in Evidence-Based Complementary and Alternative Medicine: 400mg/day of oral pumpkin seed oil in men with androgenetic alopecia produced a 40% increase in hair count versus 10% in the placebo group.

That is a well-designed study and a genuinely notable effect size. The caveats are real, too: 76 men, all male, 24 weeks, single trial, not independently replicated at scale.

The proposed active is beta-sitosterol, a plant sterol structurally similar to cholesterol and studied in the lab for its 5αR-inhibitory activity. Beta-sitosterol is the common thread linking pumpkin seed oil, saw palmetto, and pygeum — which is worth knowing, because stacking three supplements that share one mechanism is not the same as addressing three mechanisms.

Green tea EGCG

Epigallocatechin-3-gallate is the principal catechin of green tea. Kwon and colleagues (2007), in Phytomedicine, demonstrated that EGCG promoted human hair follicle growth in ex vivo culture, with evidence pointing to dermal papilla cell proliferation and protection against apoptosis, alongside 5αR-inhibitory activity (Kwon et al., 2007).

The strength here is that it used human hair follicles, not mouse skin — meaningfully more relevant than most preclinical hair data. The limitation is that ex vivo culture is not a person, and there is no adequately powered randomized human trial of EGCG for pattern hair loss. EGCG's antioxidant and anti-inflammatory activity gives it a second plausible role in quieting perifollicular inflammation, which is a legitimate co-target.

I would call EGCG mechanistically interesting and clinically unproven. That is not a dismissal; it is an accurate label.

Zinc

Zinc is essential to hair, and its role is frequently overstated in one direction and underappreciated in another.

Zinc is a required cofactor for DNA and protein synthesis in the fastest-dividing cells in the follicle matrix, and it has documented in vitro 5αR-inhibitory activity. Kil and colleagues (2013), in Annals of Dermatology, found significantly lower serum zinc in patients with several hair loss types compared with controls.

But here is what matters clinically: correcting a deficiency and supplementing beyond sufficiency are entirely different interventions. If your zinc is low, correcting it can meaningfully help your hair. If your zinc is normal, more zinc will not block your DHT — and chronic high-dose zinc supplementation induces copper deficiency, which itself causes hair and neurological problems. Zinc belongs in a hair regimen at nutritional, not pharmacologic, doses. Test rather than guess.

Pygeum (Prunus africana)

Pygeum bark extract is widely marketed for hair. Its evidence base is almost entirely in benign prostatic hyperplasia, where a Cochrane review found modest symptomatic improvement (Wilt et al., Cochrane review). It contains beta-sitosterol and other phytosterols, which is the basis for the extrapolation.

But BPH and androgenetic alopecia are different tissues with different isoform distributions, and I am not aware of a controlled human trial of pygeum for hair loss. Its presence on a DHT-blocker label is an inference, not a finding. Extrapolating from prostate data to scalp data is exactly the kind of reasoning this article is trying to talk you out of.

Honorable mentions and things I'd skip

Rosemary extract, nettle root, and reishi mushroom all appear in DHT-blocker formulas with in vitro or animal-level 5αR data and essentially no controlled human hair trials. Not fraudulent — just early. Buy them as plausible ingredients, not as proven ones.

The Distinction Nobody Explains: Oral Versus Topical

Consider what oral 5αR inhibition asks of the body. Swallow the compound and it enters systemic circulation and reaches every tissue expressing the enzyme: prostate, skin, liver, central nervous system, gonads. You are suppressing an endocrine pathway body-wide in order to affect a few square inches of scalp.

That is a poor targeting ratio. The tissue you care about is the scalp dermal papilla. Everything else is collateral exposure.

Topical application inverts it. Delivered into the scalp, the compound acts where the enzyme is doing the damage, with systemic exposure limited by the stratum corneum — which is precisely what makes topical dosing viable at all.

The general clinical principle: when a disease is local, local treatment is preferable, all else equal. Androgenetic alopecia is a local disease of follicular androgen sensitivity, not a disease of high circulating androgens. Most women with female pattern hair loss have entirely normal serum androgens. The abnormality is in the follicle's local enzymatic and receptor environment.

This is one reason I formulate topically. It is also why the "DHT blocker" pills that dominate search results strike me as the least elegant solution available: maximum systemic exposure aimed at a target that is a few millimeters below the skin surface.

For Women of Reproductive Age: Why This Distinction Is Not Optional

If you are a woman who could become pregnant, the section above is not a preference discussion. It is the decisive fact.

Finasteride and dutasteride are teratogenic. Both are contraindicated in women who are or may become pregnant. The mechanism is direct and unambiguous: DHT is essential to normal development of the male external genitalia in utero. A drug that blocks its production can cause abnormalities of the external genitalia in a male fetus. This is not a theoretical risk extrapolated from animals; it is the predictable pharmacological consequence of the drug's mechanism.

The warnings go further than most people realize. Women who are or may become pregnant are advised not to handle crushed or broken finasteride tablets, because the active can be absorbed through skin. Dutasteride, with its very long half-life, carries the additional caution that treated men should not donate blood for a defined period.

The practical result is that the most effective pharmaceutical option in pattern hair loss is unavailable to a large population of exactly the women who need help: women in their twenties, thirties, and early forties who are pregnant, breastfeeding, planning a pregnancy, or simply not willing to accept that risk profile. Add the women who don't tolerate the drug, and the underserved group is very large.

Here is why the botanical topical route matters so specifically. A topical botanical with laboratory-studied 5αR-inhibitory activity, applied to the scalp, does not create the systemic androgen suppression that produces the teratogenic risk. The mechanism of harm with finasteride is systemic fetal DHT deprivation. A local, non-pharmaceutical approach is a fundamentally different exposure situation.

I want to be exact rather than reassuring: this is a difference in the nature of the exposure, not a safety clearance. If you are pregnant, breastfeeding, or trying to conceive, review everything you apply or swallow — including botanicals and supplements — with your obstetrician before you begin. Botanical does not mean inert, and pregnancy is not the time to reason from mechanism alone. And our own line is the same one: because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.

What I will say confidently is this: for the woman of reproductive age who has been told that the effective option isn't available to her and left with nothing, "nothing" was never the only honest answer. A locally directed, drug-free approach addressing scalp DHT, perifollicular inflammation, microcirculation, and nutritional status is a legitimate strategy — and it is the population I have spent nearly two decades formulating for.

Verbascoside: A Different Angle on the Same Problem

One more compound belongs in this discussion, and it is the one closest to my own work. It also does not belong in the enzyme column, and I want to be clear about that before I say anything good about it.

Verbascoside (also called acteoside) is a phenylethanoid glycoside found in a number of plants. It is well described in the phytochemistry literature as a potent antioxidant with documented anti-inflammatory activity (Alipieva et al., 2014).

What makes it interesting for hair specifically is not an enzyme assay but a cell one. In controlled laboratory studies on human dermal papilla cells — the cells at the base of the follicle — verbascoside induced cell proliferation, prevented testosterone-induced cell death, and reduced the release of pro-inflammatory signals including IL-1α, IL-6, IL-1β and TNF-α (Wisuitiprot et al., 2022). Read that carefully, because it is a different kind of statement from everything above it in this article. Every other compound here was measured against the enzyme that makes DHT. This one was measured against what happens to the follicle's own cells when testosterone reaches them — and it kept them alive, and quieted the inflammatory signalling around them.

Two honest caveats, in the same breath. These are cell studies, not human trials, and the authors state that clinical study is still needed. And the verbascoside in that work was extracted from Acanthus, not from lilac — the same molecule from a different plant, not a study of our own material.

I'll hold to the same standard I've applied to every other ingredient here: a laboratory finding is a reason for interest and a rationale for formulation. It is not a claim about what will happen on your head. We have written up the formulation reasoning in detail on the pillar page — The Science of Verbascoside — and I'd rather you read the mechanism there and judge it yourself than take a headline from me.

The Bottom Line

The honest scorecard on natural DHT blockers looks like this. Saw palmetto has the best human evidence and performed at roughly half the efficacy of finasteride in a two-year comparison — meaningful, and not equivalent. Pumpkin seed oil has one good placebo-controlled trial with a striking effect size and no large replication. EGCG has real human follicle data ex vivo and no adequate clinical trial. Zinc matters if you're deficient and does nothing useful if you aren't. Pygeum is borrowed from prostate research and has essentially no hair trial behind it.

That is a category with genuine signal and genuine limits. Natural DHT blockers are not a pharmaceutical equivalent, and any brand telling you otherwise is not reading its own citations. What they are is a legitimate, evidence-informed option — particularly delivered topically, where the enzyme actually is, and particularly for the enormous population of women for whom the pharmaceutical route is contraindicated by pregnancy risk.

And here is the part I'd underline if I could underline only one thing: DHT is one driver among several. In my experience the women who get the best results are not the ones who found the strongest blocker. They are the ones who corrected their ferritin and thyroid, fed their follicles properly, quieted their scalp, and then addressed the androgenic signal locally and consistently for a full year. Get the labs. Then build the regimen. Then be patient — the hair cycle does not negotiate.

Dr. Susan Lin's Clinical Perspective

"The natural DHT blocker category frustrates me because the truth is more interesting than the marketing. Rossi's two-year comparison found saw palmetto improved roughly 38% of men versus 68% on finasteride — that is a real botanical effect and an honest gap, and I would rather tell a patient that number than sell her a fantasy of equivalence. What genuinely changes clinical practice is not potency, it's route. Pattern hair loss is a local disease of follicular androgen sensitivity; most of my female patients have entirely normal serum androgens. Swallowing a systemic 5αR inhibitor to treat a few square inches of scalp is poor targeting, and for any woman who could become pregnant, finasteride and dutasteride are simply not on the table. That population — young women told the effective option isn't available to them and offered nothing else — is why I formulate topically, and it has been the whole point of my work since 2008."

— Dr. Susan F. Lin, M.D., Physician Formulator, MD HAIR

Mechanism Spotlight: Two Isoforms, Two Targets — Why Type I and Type II Both Matter

Most discussion of DHT blockade collapses 5-alpha-reductase into a single enzyme. It isn't one, and the difference has real consequences for what a formulation should try to do.

Type II 5αR is concentrated in the dermal papilla of scalp hair follicles, in the prostate, and in genital skin. It is the isoform most directly implicated in androgenetic miniaturization, and it is the primary target of finasteride. Type I 5αR predominates in sebaceous glands and skin more broadly — including the sebaceous glands attached to hair follicles, which sit in intimate contact with the follicular unit and contribute meaningfully to the local androgen milieu of the scalp. Dutasteride's broader efficacy relative to finasteride is generally attributed to inhibiting both.

Sawaya and Price established the clinical relevance directly: follicles from balding scalp show a measurably different profile of 5αR Type I and Type II, aromatase, and androgen receptor compared with non-balding scalp (Sawaya & Price, 1997). The disease is written in local enzyme expression, not in serum hormone levels — which is why women with entirely normal circulating androgens still develop female pattern hair loss, and why a blood test that comes back "normal" does not mean androgens are uninvolved.

For a topical formulator, that argues for breadth rather than selectivity — and for not assuming the enzyme is the only place worth engaging. An ingredient that acts downstream of it is addressing the same disease from the other end: verbascoside is of interest here because, in laboratory studies on human dermal papilla cells, it prevented testosterone-induced death of those cells and reduced the release of pro-inflammatory signals, alongside documented antioxidant and anti-inflammatory activity (Wisuitiprot et al., 2022; Alipieva et al., 2014) — engaging the consequence of the androgenic signal and the inflammatory environment that travels with it, in the tissue where both are happening.

MD HAIR Product Recommendation

MD Nutri Hair™ Supplement

If this article has a single practical instruction, it's that DHT is one driver among several — and the one most people neglect while chasing blockers is the nutritional substrate the follicle needs to build hair at all. Blocking a signal accomplishes nothing if the raw materials aren't there.

MD Nutri Hair™ is the oral foundation of the MD® system, formulated to support the micronutrient status that the rapidly dividing cells of the follicle matrix depend on — including zinc at nutritional rather than pharmacologic levels, which is the appropriate way to use it. It also carries the standardized lilac verbascoside discussed above: the molecule that, in laboratory studies on human dermal papilla cells, prevented testosterone-induced death of those cells and reduced the release of pro-inflammatory signals including IL-1α, IL-6, IL-1β and TNF-α. That is the reason it belongs in an article about DHT — not because it blocks an enzyme, which I have not claimed and will not, but because the androgenic signal's damage and the inflammation around it are both worth addressing. One capsule daily. It is the layer I ask patients to establish first, then keep running continuously underneath whatever topical or stimulus-based work they add.

In a 30-day in-office consumer use study of MD Nutri Hair™ in 30 subjects, 95% saw improved hair appearance, 90% reported better manageability, and 75% reported increased fullness — self-reported, with no placebo control. Individual results vary. Physician-formulated by Dr. Susan F. Lin, M.D. under the MD® mark (U.S. Reg. No. 4,471,494), physician-formulated since 2008, and manufactured in FDA-registered, GMP-compliant facilities in the USA. If you are taking prescription medication, review any supplement with your physician before starting.

Genuine MD HAIR™ and MD Nutri Hair™ products are sold only through mdhair.com, md-factor.com, and the official La Cañada Ventures, Inc. stores on Amazon and Walmart. Products bought through any other channel cannot be authenticated by us.

Learn more about drug-free hair loss treatment options at mdhair.com/pages/drug-free-hair-loss-treatment

References (click to check)

Dr. Susan F. Lin, M.D. is the physician formulator behind MD HAIR, a line of drug-free hair products by La Cañada Ventures, Inc., physician-formulated since 2008. MD HAIR™ and MD Nutri Hair™ products are cosmetics and dietary supplements; they are not intended to diagnose, treat, cure, or prevent any disease. Manufactured in FDA-registered, GMP-compliant facilities in the USA; facility registration is not product approval by the FDA. This article is for educational purposes and does not constitute medical advice. Nothing here should be used to start, stop, or change a prescribed medication — including finasteride or dutasteride — without your own physician's guidance. Women who are pregnant, breastfeeding, or planning pregnancy should review all topicals and supplements with their obstetrician.

Pregnancy and breastfeeding: because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.

MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.